Physician profile
Keith Wright
NPI 1649214537
$4,904.60
in general payments reported to CMS, 2019-2025
29 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $439 · 2021: $864 · 2022: $1,192 · 2023: $675 · 2024: $813 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952 · Grant: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.98 |
| Grant | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,299.70 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $662.32 | 2019-2025 | |
| Janssen Biotech, INC. | $318.51 | 2020-2025 | Tremfya, Remicade, Simponi |
| Leo Pharma INC. | $172.00 | 2020-2025 | Adbry, Spevigo |
| Ucb, INC. | $167.20 | 2019-2024 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $148.87 | 2019-2025 | Winlevi |
| Almirall LLC | $128.77 | 2019-2023 | Seysara |
| Pfizer INC. | $115.75 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $107.67 | 2019-2023 | Libtayo |
| Amgen INC. | $95.77 | 2019-2023 | Otezla |
| Incyte Corporation | $95.52 | 2023-2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $73.80 | 2020-2021 | |
| Lilly USA, LLC | $61.02 | 2024-2025 | Ebglyss |
| Biofrontera INC. | $58.00 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $55.04 | 2020-2025 | Cabtreo, Jublia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dusa Pharmaceuticals, INC. | $46.64 | 2019 | |
| Arcutis Biotherapeutics, INC. | $44.47 | 2023-2024 | Zoryve |
| Janssen Scientific Affairs, LLC | $35.32 | 2021 | |
| Organogenesis INC. | $34.73 | 2025 | Puraply Wound Matrix |
| Dermavant Sciences, INC. | $24.79 | 2024 | Vtama |
| Mayne Pharma Commercial LLC | $23.90 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.02 | 2025 | Spevigo |
| Hydrofera LLC | $21.69 | 2021 | |
| Dermira, INC. | $18.87 | 2019 | |
| Mission Pharmacal Company | $17.16 | 2019 | |
| Verrica Pharmaceuticals INC. | $15.44 | 2024 | Ycanth |
| Allergan, INC. | $14.42 | 2022 | |
| Organon LLC | $12.97 | 2024 | |
| Reprise Biomedical, INC. | $11.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.